This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soumian, S Articles by Gibbs, R. Search for Related Content PubMed PubMed Citation Articles by Soumian, S Articles by Gibbs, R. Social Bookmarking                   What's this?

ABCA1 and atherosclerosis

Department of Vascular Surgery, Faculty of Medicine, Imperial College, Charing Cross Hospital, London, UK, s.soumian{at}imperial.ac.uk

C Albrecht

MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK

AH Davies

Department of Vascular Surgery, Faculty of Medicine, Imperial College, Charing Cross Hospital, London, UK

RGJ Gibbs

Department of Vascular Surgery, Faculty of Medicine, Imperial College, Charing Cross Hospital, London, UK

ATP binding cassette transporter A1 (ABCA1) mediates the cellular efflux of phospholipids and cholesterol to lipid-poor apolipoprotein A1 (apoA1) and plays a significant role in high density lipoprotein (HDL) metabolism. ABCA1’s role in the causation of Tangier disease, characterized by absent HDL and premature atherosclerosis, has implicated this transporter and its regulators liver-X-receptor (LXR) and peroxisome proliferator activated receptor (PPAR) as new candidates potentially influencing the progression of atherosclerosis. In addition to lipid regulation, these genes are involved in apoptosis and inflammation, processes thought to be central to atherosclerotic plaque progression. A Medline-based review of the literature was carried out. Tangier disease and human heterozygotes with ABCA1 mutations provide good evidence that ABCA1 is a major candidate influencing atherosclerosis. Animal and in vitro experiments suggest that ABCA1 not only mediates cholesterol and phospholipid efflux, but is also involved in the regulation of apoptosis and inflammation. The complex and beneficial interactions between apoA1 and ABCA1 seem to be pivotal for cholesterol efflux. The expression of the ABCA1 is tightly regulated. Furthermore the plaque microenvironment could potentially promote ABCA1 protein degradation thus compromising cholesterol efflux. PPAR-LXR-ABCA1 interactions are integral to cholesterol homeostasis and these nuclear receptors have proven anti-inflammatory and anti-matrix metalloproteinase activity. Therapeutic manipulation of the ABCA1 transporter is feasible using PPAR and LXR agonists. PPAR agonists like glitazones and ABCA1 protein stabilization could potentially modify the clinical progression of atherosclerotic lesions.

Key Words: apolipoprotein A1 • atherosclerosis • ATP binding cassette transporter 1 • HDL cholesterol • Tangier disease

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Wong, C. M. Quinn, I. C. Gelissen, and A. J. Brown Endogenous 24(S),25-Epoxycholesterol Fine-tunes Acute Control of Cellular Cholesterol Homeostasis J. Biol. Chem., January 11, 2008; 283(2): 700 - 707. [Abstract] [Full Text] [PDF]

				C. Farke, E. Viturro, H. H. D. Meyer, and C. Albrecht Identification of the bovine cholesterol efflux regulatory protein ABCA1 and its expression in various tissues J Anim Sci, November 1, 2006; 84(11): 2887 - 2894. [Abstract] [Full Text] [PDF]